| Literature DB >> 9773264 |
C W Martin1, A H Brown, D T Baird.
Abstract
Although a combination of mifepristone and a prostaglandin is a safe, acceptable alternative to vacuum aspiration for inducing abortion in early pregnancy, the longer period of vaginal bleeding after medical abortion is a disadvantage. The present study investigated whether administration of the combined oral contraceptive pill (COC) or the injection of methotrexate at the time of abortion would shorten the period of vaginal bleeding after medical abortion. After having a medical abortion induced with mifepristone (200 mg) and 0.5 mg gemeprost pessary, 80 women were randomized to four groups of 20 women each; Group A, COC; Group B, control; Group C, 50 mg/m2 methotrexate; and Group D, placebo injection. There was no significant difference in the duration of bleeding between Groups A and B (median 14 and 17 days) or between Groups C and D (18 and 15 days), or in the amount of bleeding (4 days of heavy bleeding in each group). The first period occurred sooner in Group A who took the COC (median/range: 25/15-54 control group versus 32/16-46 days, p < 0.04). The administration of methotrexate was associated with a temporary elevation in liver enzyme concentration in one woman. It is concluded that women who wish to use COC can start immediately after medical abortion. Addition of methotrexate after abortion has no significant beneficial effect on patterns of bleeding and cannot be recommended.Entities:
Keywords: Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Biology; Bleeding; Comparative Studies; Contraception; Contraceptive Methods--therapeutic use; Developed Countries; Diseases; Drugs; Endocrine System; Europe; Family Planning; Fertility Control, Postconception; Hormone Antagonists; Hormones; Methotrexate--therapeutic use; Northern Europe; Oral Contraceptives, Combined--therapeutic use; Oral Contraceptives--therapeutic use; Physiology; Research Methodology; Research Report; Ru-486; Scotland; Signs And Symptoms; Studies; Treatment; United Kingdom
Mesh:
Substances:
Year: 1998 PMID: 9773264 DOI: 10.1016/s0010-7824(98)00072-9
Source DB: PubMed Journal: Contraception ISSN: 0010-7824 Impact factor: 3.375